RU2015150739A - Предиктивный биомаркер для терапии рака - Google Patents
Предиктивный биомаркер для терапии рака Download PDFInfo
- Publication number
- RU2015150739A RU2015150739A RU2015150739A RU2015150739A RU2015150739A RU 2015150739 A RU2015150739 A RU 2015150739A RU 2015150739 A RU2015150739 A RU 2015150739A RU 2015150739 A RU2015150739 A RU 2015150739A RU 2015150739 A RU2015150739 A RU 2015150739A
- Authority
- RU
- Russia
- Prior art keywords
- agonist
- paragraphs
- dna
- tlr
- dna construct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
Claims (17)
1. Способ прогнозирования или мониторинга ответа пациента, страдающего раком или аутоиммунным заболеванием, или ответа на лечение агонистом TLR-9 определением количества активированных натуральных киллерных Т (NKT) клеток.
2. Способ по п. 1, где агонист TLR-9 представляет ДНК конструкт, содержащий по меньшей мере один мотив последовательности N1N2CGN3N4, где N1N42 и N3N4 представляют любую комбинацию A, С, Т, и G, и C представляет дезоксицитидин, G представляет дезоксигуанозин, А представляет дезоксиаденозин а T представляет дезокситимидин.
3. Способ по пп. 1 и 2, где определяют соотношение активированных NKT-клеток от всей популяции NKT клеток.
4. Способ по любому из пп. 1 и 2, где пациент, отвечающий на лечение агонистом TLR-9, имеет по меньшей мере 3% активированных NKT-клеток от всей популяции NKT клеток.
5. Способ по любому из пп. 1 и 2, где ранее проводилась индукционная терапия с не ДНК лекарственным средством.
6. Агонист TLR-9 для применения в способе лечения рака, характеризующийся тем, что пациент имеет повышенные уровни активированных NKT-клеток.
7. Агонист по п. 6, содержащий по меньшей мере ДНК конструкт, содержащий по меньшей мере один мотив последовательности N1N2CGN3N4, где N1N2 и N3N4 представляет любую комбинацию A, C, Т, и G, и C представляет дезоксицитидин, G представляет дезоксигуанозин, А представляет дезоксиаденозин и T представляет дезокситимидин.
8. Агонист по п. 7, где N1N2 представляет элемент, выбираемый из группы, состоящей из GT, GG, GA, AT или АА, N3N4 представляет элемент, выбираемый из группы, состоящей из CT или ТТ.
9. Агонист по п. 7 или 8, где ДНК представляет линейный с открытой цепью ДНК конструкт, содержащий одно или двухцепочечную ДНК, или линейный двухцепочечный ДНК конструкт, который содержит по меньшей мере на одном конце одноцепочечную петлю.
10. Агонист по любому из пп. 7 и 8, где мотив последовательности N1N2CGN3N4 расположен в одноцепочечной и/или двухцепочечной области последовательности ДНК.
11. Агонист по любому из пп. 7 и 8, содержащий по меньшей мере один L-ДНК нуклеотид.
12. Агонист по любому из пп 7 и 8, где по меньшей мере один нуклеотид модифицирован функциональной группой, выбираемой из группы, состоящей из карбоксильной, амино, амидной, альдиминовой, кетальной, ацетальной, сложного эфира, простого эфира, дисульфидной, тиоловой и альдегидной групп.
13. Агонист по любому из пп. 7 и 8, где ДНК конструкт связан с соединением, выбираемым из группы, состоящей из пептидов, белков, углеводов, антител, липидов, мицелл, везикул, синтетических молекул, полимеров, микрочастиц, металлических частиц, наночастиц или твердой фазы.
14. Агонист по любому из пп. 7 и 8, где ДНК конструкт является частью композиции лекарственного средства.
15. Агонист по п. 14, где композиция лекарственного средства представляет вакцину.
16. Набор для прогнозирования или мониторинга ответа пациента, страдающего раком или аутоиммунным заболеванием, или ответа на лечение агонистом TLR-9, содержащий средства для определения и количественного определения активированных NKT клеток от всей популяции NKT клеток.
17. Набор по п. 15, где агонист TLR-9 содержит ДНК конструкт, содержащий по меньшей мере один мотив последовательности N1N2CGN3N4, где N1N2 и N3N4 представляет любую комбинацию A, C, Т, и G, и C представляет дезоксицитидин, G представляет дезоксигуанозин, А представляет дезоксиаденозин and T представляет дезокситимидин.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1309657.3 | 2013-05-30 | ||
| GB1309657.3A GB2514591A (en) | 2013-05-30 | 2013-05-30 | Predictive biomarker for cancer therapy |
| PCT/EP2014/059995 WO2014191222A1 (en) | 2013-05-30 | 2014-05-15 | Predictive biomarker for cancer therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015150739A true RU2015150739A (ru) | 2017-07-06 |
| RU2672358C2 RU2672358C2 (ru) | 2018-11-14 |
Family
ID=48805478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015150739A RU2672358C2 (ru) | 2013-05-30 | 2014-05-15 | Предиктивный биомаркер для терапии рака |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10006032B2 (ru) |
| EP (1) | EP3004875B1 (ru) |
| JP (1) | JP6441320B2 (ru) |
| KR (1) | KR101937442B1 (ru) |
| CN (2) | CN110201156A (ru) |
| AU (1) | AU2014273400B2 (ru) |
| BR (1) | BR112015029852A2 (ru) |
| CA (1) | CA2907980A1 (ru) |
| DK (1) | DK3004875T3 (ru) |
| ES (1) | ES2795929T3 (ru) |
| GB (1) | GB2514591A (ru) |
| HK (1) | HK1216779A1 (ru) |
| IL (1) | IL242551A (ru) |
| MX (1) | MX365512B (ru) |
| PL (1) | PL3004875T3 (ru) |
| RU (1) | RU2672358C2 (ru) |
| WO (1) | WO2014191222A1 (ru) |
| ZA (1) | ZA201506813B (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015187966A1 (en) | 2014-06-04 | 2015-12-10 | Aurasense Therapeutics, Llc | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| LU92821B1 (en) | 2015-09-09 | 2017-03-20 | Mologen Ag | Combination comprising immunostimulatory oligonucleotides |
| GB2542425A (en) | 2015-09-21 | 2017-03-22 | Mologen Ag | Means for the treatment of HIV |
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| EP3392345A1 (en) | 2017-04-22 | 2018-10-24 | Mologen AG | Biomarker for small cell lung cancer therapy |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| JP2020531555A (ja) * | 2017-08-31 | 2020-11-05 | モロゲン・アーゲー | 腫瘍微小環境のモジュレーションのためのｔｌｒ−９アゴニスト |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0314682D0 (en) * | 2003-06-24 | 2003-07-30 | Isis Innovation | Materials and methods relating to the modulation of T cell response to soluble antigen |
| WO2006015560A1 (de) | 2004-08-09 | 2006-02-16 | Mologen Ag | Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen |
| US20090220931A1 (en) * | 2005-09-08 | 2009-09-03 | Mologen Ag | Functional in vitro immunoassay |
| JP2010512421A (ja) * | 2006-12-12 | 2010-04-22 | イデラ ファーマシューティカルズ インコーポレイテッド | Ｔｌｒ９の合成アゴニスト |
| JP5357782B2 (ja) * | 2007-02-21 | 2013-12-04 | バクシネックス インコーポレーティッド | 抗原負荷ＣＤ１ｄ分子によるＮＫＴ細胞活性の調節 |
| AU2008282172B2 (en) * | 2007-08-01 | 2014-05-22 | Idera Pharmaceuticals, Inc. | Novel synthetic agonists of TLR9 |
| JP2010536787A (ja) * | 2007-08-15 | 2010-12-02 | イデラ ファーマシューティカルズ インコーポレイテッド | Ｔｏｌｌ様受容体モジュレータ |
| JP5809415B2 (ja) * | 2007-11-09 | 2015-11-10 | ペレグリン ファーマシューティカルズ，インコーポレーテッド | 抗ｖｅｇｆ抗体の組成物および方法 |
| EP2073009A1 (en) * | 2007-12-19 | 2009-06-24 | Cell Med Research GMBH | Method for T, NK and NKT cells |
| EP2711021B1 (en) | 2008-05-02 | 2016-03-09 | BliNK Therapeutics Limited | Products and methods for stimulating an immune response |
| WO2009138494A2 (en) * | 2008-05-15 | 2009-11-19 | Ablynx N.V. | Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors |
| GB0820698D0 (en) * | 2008-11-12 | 2008-12-17 | Ludwig Inst Cancer Res | Uses of immunomodulators |
| CN102421448A (zh) * | 2009-05-29 | 2012-04-18 | 霍夫曼-拉罗奇有限公司 | Her2信号传导调控剂在表达her2的胃癌患者中 |
| KR102100110B1 (ko) * | 2010-11-19 | 2020-04-14 | 이데라 파마슈티칼즈, 인코포레이티드 | 톨-유사 수용체 기반 면역 반응을 조절하기 위한 면역 조절 올리고뉴클레오타이드(ｉｒｏ) 화합물 |
| GB201021867D0 (en) * | 2010-12-23 | 2011-02-02 | Mologen Ag | Non-coding immunomodulatory DNA construct |
| SI2744826T1 (sl) * | 2011-08-16 | 2022-05-31 | Morphosys Ag | Kombinirana terapija s protitelesom proti CD19 in analogom purina |
| EP2682750A1 (en) * | 2012-07-02 | 2014-01-08 | Sotio a.s. | In vitro method for the diagnosis and surveillance of cancer |
-
2013
- 2013-05-30 GB GB1309657.3A patent/GB2514591A/en not_active Withdrawn
-
2014
- 2014-05-15 MX MX2015016305A patent/MX365512B/es active IP Right Grant
- 2014-05-15 US US14/891,869 patent/US10006032B2/en active Active
- 2014-05-15 CA CA2907980A patent/CA2907980A1/en not_active Abandoned
- 2014-05-15 CN CN201910417409.6A patent/CN110201156A/zh active Pending
- 2014-05-15 DK DK14725114.4T patent/DK3004875T3/da active
- 2014-05-15 RU RU2015150739A patent/RU2672358C2/ru not_active Application Discontinuation
- 2014-05-15 KR KR1020157029934A patent/KR101937442B1/ko active IP Right Grant
- 2014-05-15 CN CN201480024805.8A patent/CN105247365B/zh not_active Expired - Fee Related
- 2014-05-15 PL PL14725114T patent/PL3004875T3/pl unknown
- 2014-05-15 AU AU2014273400A patent/AU2014273400B2/en not_active Ceased
- 2014-05-15 WO PCT/EP2014/059995 patent/WO2014191222A1/en active Application Filing
- 2014-05-15 EP EP14725114.4A patent/EP3004875B1/en active Active
- 2014-05-15 ES ES14725114T patent/ES2795929T3/es active Active
- 2014-05-15 BR BR112015029852A patent/BR112015029852A2/pt not_active Application Discontinuation
- 2014-05-15 JP JP2016515715A patent/JP6441320B2/ja not_active Expired - Fee Related
-
2015
- 2015-09-15 ZA ZA2015/06813A patent/ZA201506813B/en unknown
- 2015-11-11 IL IL242551A patent/IL242551A/en active IP Right Grant
-
2016
- 2016-04-20 HK HK16104519.6A patent/HK1216779A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016526164A (ja) | 2016-09-01 |
| EP3004875A1 (en) | 2016-04-13 |
| ES2795929T3 (es) | 2020-11-25 |
| IL242551A (en) | 2017-07-31 |
| KR20150129860A (ko) | 2015-11-20 |
| US10006032B2 (en) | 2018-06-26 |
| RU2672358C2 (ru) | 2018-11-14 |
| CN105247365B (zh) | 2019-06-18 |
| AU2014273400B2 (en) | 2017-02-23 |
| DK3004875T3 (da) | 2020-06-08 |
| MX2015016305A (es) | 2016-03-21 |
| JP6441320B2 (ja) | 2018-12-19 |
| CN110201156A (zh) | 2019-09-06 |
| BR112015029852A2 (pt) | 2017-07-25 |
| HK1216779A1 (zh) | 2016-12-02 |
| EP3004875B1 (en) | 2020-03-04 |
| WO2014191222A1 (en) | 2014-12-04 |
| MX365512B (es) | 2019-06-05 |
| GB201309657D0 (en) | 2013-07-17 |
| ZA201506813B (en) | 2017-01-25 |
| CN105247365A (zh) | 2016-01-13 |
| PL3004875T3 (pl) | 2020-11-16 |
| US20160115479A1 (en) | 2016-04-28 |
| CA2907980A1 (en) | 2014-12-04 |
| KR101937442B1 (ko) | 2019-01-11 |
| GB2514591A (en) | 2014-12-03 |
| AU2014273400A1 (en) | 2015-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015150739A (ru) | Предиктивный биомаркер для терапии рака | |
| BR112014000965B8 (pt) | Método, aparelho e meio de armazenamento não transitório | |
| CY1120434T1 (el) | Πρωτεϊνες προσδεσης il-1 | |
| JP2014005231A5 (ru) | ||
| EA201690421A1 (ru) | Положительный эффект в форме увеличения продолжительности жизни у больных с солидными опухолями с повышенными уровнями c-реактивного белка | |
| BR112014009269A8 (pt) | diagnóstico de aneuploidia cromossômica fetal | |
| EA201591817A1 (ru) | Не содержащая сыворотки среда для культивирования клеток | |
| JP2014144959A5 (ru) | ||
| CY1121964T1 (el) | Αντισωματα εναντιον toy csf-1r | |
| EA201270571A1 (ru) | Человеческие il-23-антигенсвязывающие белки | |
| EP4220170A3 (en) | Method for detecting a solid tumor cancer | |
| CN107075585A8 (zh) | 具有锁核酸的序列转换和信号扩增dna以及使用其的检测方法 | |
| EA201690537A1 (ru) | Способы и средства для введения контрастной среды | |
| RU2018100104A (ru) | Клетки в качестве модели для идентификации возможных модуляторов вкусовых ощущений | |
| ES2689084T3 (es) | Método de diagnóstico de la galactosemia en un cribado neonatal | |
| RU2017132274A (ru) | Способы диагностирования хронического заболевания клапанов | |
| Ahrens et al. | Quantitative proteomics: a central technology for systems biology | |
| Kaminskiy et al. | Development of test-benches for control and research tests of turbochargers | |
| Angiolilli et al. | A1. 20 HDAC5 regulates CXCL chemokine expression in RA FLS via the transcription factor IRF1 | |
| Bryzgalova | The feuilletons by Don-Аминадо | |
| Filatov | Country leaders prospecting part of studying about deposits | |
| Popov et al. | Clinical and pathogenetic significance of serum resistin determination in osteoarthritic patients | |
| 井手迫 et al. | The MicroRNA Expression Signature of Bladder Cancer by Deep Sequencing: The Functional Significance of the miR-195/497 Cluster | |
| Lenjo et al. | Correlational dependence between indices of acid base State of blood and urine of cows, which have ketosis | |
| RU2011133107A (ru) | Способ прогнозирования течения неспецифических вульвовагинитов у девочек |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20171002 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20180226 |
|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20210728 |